Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.

Hasvold, L P

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients. [electronic resource] - Journal of human hypertension Nov 2014 - 663-9 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1476-5527

10.1038/jhh.2014.43 doi


Aged
Angiotensin II Type 1 Receptor Blockers--therapeutic use
Angiotensin-Converting Enzyme Inhibitors--therapeutic use
Benzimidazoles--therapeutic use
Biphenyl Compounds
Blood Pressure--drug effects
Cardiovascular Diseases--diagnosis
Diabetes Mellitus, Type 2--diagnosis
Enalapril--therapeutic use
Female
Humans
Hypertension--diagnosis
Incidence
Male
Middle Aged
Primary Health Care
Retrospective Studies
Risk Factors
Sweden--epidemiology
Tetrazoles--therapeutic use
Time Factors
Treatment Outcome